JACC-Heart Failure

Article	Citations
Eating to Prevent Both Heart and Planetary Failure	214
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	165
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	159
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	149
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	115
Correction	94
Reply	91
Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure	83
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	75
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	71
Editorial Board	70
Wearable Remote Patient Monitoring Devices	65
Reply	62
Developing a System for Best Performance for Cardiac Transplantation	62
Long-Term Effects of Sotatercept on Right Ventricular Function	60
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	58
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	53
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	52
Predictors of Incident Heart Failure Diagnosis Setting	51
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	51
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	49
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	49
Opportunities for Change in Home Health Care in Heart Failure	48
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF	48
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	46

Curing Ourselves of Toxic Positivity for Hospital-at-Home	46
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	44
Challenges Addressing Prognosis in Advanced Heart Failure	44
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	43
A Woman's Work Is Never Done	41
Thank You for the Privilege	41
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	41
Racial and Genetic Differences	40
Reply	40
The Urgent Need for More Cardiac Rehabilitation in the Aim to “Preserve” Patients With Heart Failure	40
Mitral Regurgitation in Heart Failure	38
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	37
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	36
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	36
Pragmatic Design of Randomized Clinical Trials for Heart Failure	36
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	35
Heart Failure in Women	35
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	35
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	35
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	34
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	34
Advanced Heart Failure in the Cardiac Intensive Care Unit	33
NT-proBNP	33
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	32
Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation	32
The Path Toward a More Equitable Transplant System	32
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	32
Reply	31
Heart Failure With Preserved Ejection Fraction	31
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	31
STRONG-HF	30
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	30
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	30
Compensation Models in Heart Failure	30
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	29
Body Composition and Survival in Patients With Heart Failure	29
Full Issue PDF	29
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	29
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	29
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	29
Reevaluating Growth Hormone Therapy in HFrEF	28
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	28
Every Journey Needs a Guide	28
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	28
Upper Body Hypoxemia During ECMELLA	28
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	27
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	25
Understanding and Investigating Sex-Based Differences in Heart Transplantation	25
Obesity and Weight Loss Strategies for Patients With Heart Failure	25
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	25

Management of Heart Failure–Related Cardiogenic Shock	24
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	24
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	24
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	23
Chloride in Heart Failure	23
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	23
Therapeutic Options in Ambulatory Advanced Heart Failure	22
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	22
Smoking Cessation Reduces the Risk of Heart Failure	22
Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure	22
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	22
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	22
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	21
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	21
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction	21
Full issue PDF	21
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	21
Full issue PDF	20
Bounded Rationality and Clinical Guidance Documents for Heart Failure	20
To ‘Plant or Not to ‘Plant, That Is the Question	20
Walking the Line Between Failure and Remission	20
Instructions for Authors	20
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	20
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	19
Worsening Heart Failure Events in HFpEF	19
Jump Starting the Heart	19
Reply	19
Redefining Pre–Heart Failure With Cardiac Biomarkers	19
Tafamidis in Octogenarians	18
Isolating Noise From Signals in the Air	18
Critical Importance of Genetic Screening in Family Members	18
From Better Models to Better Care	18
Treatment of Obesity in Heart Failure	18
Setting the Diagnosis of Heart Failure	17
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	17
To Infinity and Beyond	17
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	16
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	16
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	16
Illuminating a Hidden Risk	16
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction	16
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes	16
Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure	16
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	16
Editorial Board	16
A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support	15
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	15
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	15
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of HFrEF	15
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF	15
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	15
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	15
Reply	15
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	14
Full Issue PDF	14
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	14
Physical Activity Trajectories Preceding Incident Heart Failure	14
The Link Between Heart Failure and Neurodegeneration	14
Reply	14
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	14
Istaroxime in HFpEF	14
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	14
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	13
Articulating the JACC Journals’ Direction in Times of Global Change	13
Cardiac Resynchronization Therapy in Nonischemic Cardiomyopathy	13
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	13
Targeting Inflammation in Heart Failure Prevention	13
Bereavement and Mortality in Heart Failure	13
Correction	13
Deactivation of Left Ventricular Assist Devices at the End of Life	13
Low Serum Ferritin Might Predict Incident Heart Failure	13
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	13
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	13
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	13
Impact of Female Sex on Cardiogenic Shock Outcomes	13
Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy	13
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	13
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	13
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	13
Reply	12

Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	12
Reducing Pediatric Heart Failure Readmissions	12
Shedding Light on the Darkness of MYH7 Cardiomyopathies	12
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	12
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	12
Correction	12
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	12
Reply	12
Information for Authors	11
Aging in Heart Failure	11
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	11
Bio-Profiling of Transthyretin Amyloid Cardiomyopathy	11
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	11
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	11
Missing the True Target in Advanced Heart Failure	11
Contemporary American and European Guidelines for Heart Failure Management	11
Redefining Boundaries in Heart Failure Care	10
Call for Fine Remote Monitoring of Prognostic Signs and Symptoms in Heart Failure	10
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	10
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	10
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	10
Correction	10
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	10
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	10
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	10
The Vexing Problem of HFpEF Therapeutics	10
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	10
Empower the Future… Even Oprah Had a Mentor!	10
The HeartMate 3 Risk Score	10
Insights From the History and Physical Examination in HFpEF or HFrEF	10
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	10
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	10
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	9
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure	9
Pulse Pressure Augmentation During Exercise	9
But Is All Post-Transplant Lymphoproliferative Disorder Created Equal?	9
“Pharmacoequity” in Heart Failure Treatment	9
Left Atrial-to-Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	9
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction	9
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	9
Reply	9
Officers Page	9
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	9
Encouraging Data Encourage More Research on Optimal Medical Therapy for Patients With HFrEF	9
Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials	9
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	9
Renal Compression in Heart Failure	9
Change Is the Only Constant in Heart Failure	9
Survival of the Fittest	9
Measures to Improve Trial Enrollment	9
Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure	9
Can We Manage Presymptomatic TTR V142I Related Risk?	9
Pregnancy as a Sentinel Event	9
Toward Equitable Heart Transplant Outcomes	8
Donor Diabetes Mellitus Status and Contemporary Outcomes After Cardiac Transplantation	8
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)	8
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	8
Targets for Success in Treatment of Patients Hospitalized for Heart Failure	8
Migration Matters	8
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin	8
Instructions for Authors	8
Reply	8
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction	8
Correction	8
Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment	8
Moving the Goalposts to Improve Postdischarge Outcome for Patients With Cardiogenic Shock and Acute MI	8
Prevalence and Prognostic Impact of Drug Use in Patients Hospitalized for Acute Heart Failure	8
Building Better Defects	8
How to Make the Transplantation Allocation System Better	8
Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation	8
Emerging Opportunities to Reduce Racial, Ethnic, and Gender Disparities in Advanced Heart Failure Care	8
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF	8
Barriers and Facilitators to Prescribing Guideline-Directed Medical Therapy for Heart Failure in the Indian Health Service	8
Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction	8
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA	8
The Quagmire of Prognostication in Heart Failure	8
Ending the Fear Depriving Patients With HFpEF and CKD of Lifesaving Therapies	8
Difficult Diagnoses Are Often Undertreated	7
Predicting the Future for AL Amyloidosis Patients With Cardiac Involvement	7
Full issue PDF	7
Female Reproductive Factors and Risk of New-Onset Heart Failure	7
“We Are the Champions”	7
Function Follows Form	7
Sex Differences in Myocardial Histology, Gene Expression, and Myocardial Recovery in Recent-Onset Cardiomyopathy	7
Full issue PDF	7
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality	7
Sequential Evaluation of NT-proBNP in Heart Failure	7
Trends in B-Type Natriuretic Peptide Testing	7
Sodium-Glucose Cotransporter Inhibitors in Heart Failure	7
Reply	7
Editorial Board	7
Centrally Adjudicated Heart Failure Outcomes Are Needed in Clinical Trials	7
Imagine Quality Heart Failure Care, I Wonder If You Can	7
Reply	7
Comprehensive Investigation of Latent Pulmonary Vascular Disease	7